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whether during normal cell growth or after 
genotoxic stress, there is a continuous battle 
between survival and death that determines 
cell fate. Tumor cells have acquired enhanced 
anti-apoptotic and pro-survival properties 
that make them resistant to cancer therapy. 
it is well-established that AKT is hyperacti-
vated in many cancers, and that this protects 
against cell killing in response to DnA damag-
ing agents, including ionizing radiation (iR). A 
plethora of events are triggered in response 
to iR, including the DnA damage response 
(DDR), apoptosis/death as well as pro-survival 
signaling via eRK and Pi3K/AKT.1 Many labo-
ratories have reported that iR activates AKT 
(seen as increased levels of AKT phosphoryla-
tion at s473 and T308). ATM (ataxia telangi-
ectasia mutated), the master regulator of the 
DDR, in part controls insulin and iR-induced 
phosphorylation of AKT,2,3 and AKT has been 
shown to regulate DsB repair in a number of 
different cell systems.4-8 However, it is unclear 
how the DDR signal originating from DsBs is 
transduced to AKT. 
The article by Fraser et al. published in the 
July 1st issue of Cell Cycle reports that MRe11 
promotes the accumulation of phosphory-
lated AKT (s473) at DsBs via ATM.9 They dem-
onstrated that AKT is important for conferring 
radioresistance and for promoting the liga-
tion of linearized plasmids in vitro, suggest-
ing that AKT might facilitate the resealing of 
DsBs, thereby enhancing cell survival. Using iR, 
nuclear Uv laser micro-irradiation or an induc-
ible restriction endonuclease to induce DsBs, 
they showed that pAKT (s473), but not pAKT 
(T308) or total AKT, accumulated in the vicinity 
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of iR-induced DsB and colocalized with γH2AX 
and pATM (s1981). 
Knowing that MRe11-RAD50-nBs1 (MRn) 
is positioned upstream of ATM, they knocked 
down MRe11 expression and showed that 
pAKT (s473) foci formation was dependent 
on MRe11. However, MRe11 did not require 
the MRe11 endonuclease domain, suggest-
ing that DnA resection was not necessary 
to attract pAKT to repair centers. They went 
on to show that the histone ubiquitin ligase 
RnF168 was also required for DsB-induced 
pAKT localization. However, DnA-PKcs, Pi3K 
and ATR were not. These results demonstrate 
that DsBs activate a signaling cascade that 
directly promotes a Pi3K-independent path-
way of AKT phosphorylation that is dependent 
on MRe11-ATM-RnF168 signaling. Altogether, 
the authors suggest that ubiquitin-dependent 
and DnA-PKcs-independent non-homologous 
end joining (nHeJ) repair is the target for pAKT.
what remains unclear is whether the global 
effects resulting from AKT knockdown on 
radiosurvival can be fully accounted for by 
the relatively small fraction of total AKT that 
localized to DsBs as pAKT (s473). Furthermore, 
is nHeJ specifically influenced by AKT, or is 
homologous recombination repair (HRR) also 
affected? since resection was not necessary 
for attracting pAKT to repair foci, this might 
argue against a role for HRR. As the kinetics 
of foci removal was not closely examined in 
the study (except for a single 24 h time point), 
it is difficult to say whether the presence of 
pAKT at DsBs influences repair in vivo. Another 
question is the role of other AKT isoforms. 
Only AKT1 was manipulated by RnAi. it would 
be interesting to know whether AKT2 and 
AKT3, two other very similar AKT isoforms 
that provide overlapping and back-up roles 
to AKT1, influence pAKT foci localization and 
repair. Most commercially available antibodies 
against pAKT (s473) also recognize phosphor-
ylated AKT2 (s474) and AKT3 (s472). Thus, the 
roles of AKT2 and AKT3 in this response, if any, 
should be explored further. 
The results by Fraser et al. are complemen-
tary to recent findings by Khalil et al.,10 who 
demonstrated that DsBs resulting from BrdU 
photolysis or endonuclease electroporation 
triggered an ATM-dependent, pro-survival sig-
naling cascade. This cascade required func-
tional AKT in order to transmit the signal 
to MeK/eRK and promote cell proliferation. 
Collectively, conclusions from these two stud-
ies add weight to the notion that after low 
levels of DnA damage pro-survival signaling 
might be yet another arm of the DDR regu-
lated by ATM. Thus, AKT could play the role 
of gatekeeper, somehow weighing cues from 
the DDR and growth factor signaling, to make 
balanced decisions together with ATM as to 
whether a cell will repair its DnA and live or be 
unable to and die.
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The imbalance between oxygen delivery and 
consumption results in hypoxia (low oxygen 
concentration), a hallmark of human cancers 
that contributes to resistance to radiation 
therapy and chemotherapy and ultimately to 
poor patient prognosis. The master regulator 
of the adaptive response to oxygen depriva-
tion is hypoxia-inducible factor-1 (HiF-1), a 
transcription factor that operates by activating 
the expression of genes related to angiogen-
esis, glycolytic metabolism, oxygen consump-
tion, migration and invasion.1 HiF-1 protein 
complex consists of a β subunit, which is 
constitutively expressed, and a HiF-α subunit 
that is oxygen responsive and regulated by 
ubiquitin-proteasomal degradation. HiF-1a is 
frequently overexpressed in human cancers 
and is an attractive target for therapy.2
HiF-1α has also been implicated in a non-
canonical pathway that does not require DnA 
binding activity and counteracts the effects of 
c-Myc on gene expression. indeed, work from 
Huang’s laboratory has provided evidence that 
the PAs (Per-ARnT-sim)-B domain of HiF-1α is 
responsible for inhibiting the c-Myc-depen-
dent expression of MSH2 and NBS1, enzymes 
involved in DnA mismatch and double-strand 
break repair, respectively.3 Thus, the HiF-α-
c-Myc pathway seems to act as an essential 
component in mediating genetic instability in 
a hypoxic environment that promotes tumor 
progression.4
These results, however, raised the impor-
tant question as to whether normal tissues 
would respond differently to the selection 
pressure toward genetic instability exerted 
by the hypoxic environment. in the July 15th 
issue of Cell Cycle, Hayashi and her colleagues 
pursued this question by looking at one of the 
major features of cancer, evasion of apoptosis 
and whether non-cancerous cells would expe-
rience similar accumulation of genetic altera-
tions induced by the HiF-1α-c-Myc pathway, 
or whether these normal cells would somehow  
be protected.5 indeed, they found that hypoxia 
or HiF-1α expression inhibited DnA repair 
and induced DnA damage in all malignant 
and benign mouse cells tested. However, only 
apoptosis-deficient malignant cells accumu-
lated DnA damage and acquired anchorage-
independent growth and features consistent 
with epithelial-mesenchymal transition (eMT), 
implicating a protective function of apoptosis 
against HiF-1α-induced malignant develop-
ment. Furthermore, the growth advantage 
observed was further associated with resis-
tance to etoposide treatment, at least in part 
attributed to increased Akt activity and inhibi-
tion of autophagy, thus, once again, implicat-
ing the HiF-1α-c-Myc pathway in promoting 
the survival of apoptosis-deficient malignant 
cells. Taken together, Hayashi et al. provide 
evidence that normal cells proficient in apop-
tosis are, for the most part, safe under hypoxic 
stress, and genetic alteration produced by 
HiF-1α is largely cell-context dependent.
The contribution of HiF to tumor pro-
gression is largely attributed to its ability to 
induce the expression of genes whose prod-
ucts contribute to essential features of the 
malignant phenotype, including metabolic 
reprogramming, angiogenesis and metastasis. 
The elegant work of Hayashi and his col-
leagues extends the involvement of HiF-1α in 
tumorigenesis by implicating a non-canonical 
mechanism of action that counteracts c-Myc 
effects on gene expression. However, to what 
extent this pathway is active in the presence of 
deregulated or oncogenically activated c-Myc 
remains to be established. indeed, under these 
circumstances, the interaction between HiF 
and c-Myc appears to be much more com-
plex.6 For instance, HiF-1 and c-Myc can coop-
erate for the induction of glycolytic enzymes 
or angiogenic factors, and HiF-2 enhances 
c-Myc transcriptional activity in renal cell 
carcinogenesis.7
The work published by Hayashi et al. in the 
July 15th issue of Cell Cycle is consistent with 
a model in which apoptosis proficiency is a 
gatekeeper to limit the potential damaging 
genetic changes effected by a hypoxic micro-
environment. indeed, evidence has been 
provided that HiF-1α may induce apoptosis, 
although the context in which this occurs 
and the pathways implicated are still poorly 
understood. evasion of apoptosis is a hallmark 
of human cancers and selection of geneti-
cally altered, apoptosis-resistant clones by 
hypoxia has been previously suggested.8 The 
interplay between cell-autonomous genetic 
changes and the selection pressure exerted 
by the tumor microenvironment is crucial 
to fully execute the tumorigenic program. 
Hayashi and colleagues provide further exper-
imental evidence to corroborate a critical 
role played by the HiF-1α-c-Myc pathway in 
tumorigenesis.
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The subventricular zone (svZ) of the lateral 
ventricles and the subgranular zone of the 
dentate gyrus (DG) of the hippocampus are 
well-characterized germinal niches of the 
central nervous system (Cns), in which stem 
cells support neurogenesis and gliogenesis 
throughout adult life. The maintenance and 
differentiation of brain stem cells is orches-
trated by cellular contacts to the basal lamina, 
which acts as a scaffold, sequestering and/or   
modulating soluble factors derived from local 
cells.1
while investigating the molecular basis 
of the cognitive decline that follows cranial 
radiation as adjuvant treatment of primary 
brain tumors in humans, Monje et al. first 
observed that experimental cranial irradiation 
significantly altered neurogenesis in the rat 
DG. The irradiation-disrupted stem cell niche 
had a remarkable decrease of blood vessel-
associated clusters of proliferative neural pro-
genitors as well as a significant increase of 
activated microglia. This microglial phenotype 
led to the hypothesis that inflammation may 
perturb the endogenous stem cell compart-
ment and, ultimately, neurogenesis.2 The same 
authors developed a model of lipopolysaccha-
ride (LPs)-induced inflammation characterized 
by a significant impairment of hippocampal 
neurogenesis mediated by activated microglia 
releasing interleukin-6 in the DG.3 striking 
restoration of DG neurogenesis was achieved 
by either decreasing microglial activation with 
the non-selective inhibitor of cyclooxygen-
ase (COX)-1 and COX-2 indomethacin3 or with 
metabolites/chaperones that protect mito-
chondrial function.4
Following these first reports, we showed 
that in chronic experimental autoimmune 
encephalomyelitis (eAe), persistent Cns 
inflammation impaired the proliferative and 
migratory properties of svZ-resident stem 
cells, leading to significant accumulation of 
non-migratory neuroblasts within the svZ.5 
However, when challenged within a relaps-
ing-remitting eAe model, the svZ stem cell 
compartment underwent significant acute 
increase of proliferation, migration and oli-
godendrogenic potential. This was lost along 
with progression towards more chronic dis-
ease stages. interestingly, activated microglial 
cells were found closely associated with Cns 
stem and progenitor cells in the dysfunctional 
eAe svZ, and delayed (i.e., started 20 days after 
immunization) treatment with the microglial 
modulator minocycline reduced the number 
of microglia while increasing the proliferation 
in the svZ.6 
These data indicate that adult neural stem 
cell physiology is greatly influenced by the 
cross-talk between the immune system and 
the Cns, and suggest that both states of per-
sistent hyper- or underactivation (e.g., under 
immune deficiencies) of the immune system 
may lead to dysfunction of the Cns stem cell 
compartments.
Beyond the holistic (but true) view that 
soluble factors released by immune cells 
greatly affect stem cells, there is also parallel 
evidence that Cns stem cells express func-
tional immune-like molecules, such as cell 
adhesion molecules, chemokine receptors and 
Toll-like receptors (TLRs), that enable them to 
interact with the inflamed Cns microenviron-
ment. interestingly, TLR2 and 4 also orches-
trate proliferation and differentiation of Cns 
stem cells, with TLR2 being a positive regula-
tor of neurogenesis only and TLR4 acting as 
a negative regulator of both proliferation and 
neurogenesis.7 
COX-1 is another very interesting candidate 
to study when looking at neuro-immune inter-
actions at prototypical Cns stem cell niches. 
A previous study from Bosetti and colleagues 
investigated the critical role of COX-1 in the 
neuroinflammatory response to intracerebro-
ventricular LPs and established that either 
gene ablation or pharmacological inhibition of 
COX-1 significantly reduced microglial activa-
tion, release of pro-inflammatory and oxida-
tive stress mediators as well as blood-brain 
barrier disruption and recruitment of periph-
eral leukocytes.8
in the August 1st issue of Cell Cycle, Russo 
and colleagues revealed a role of COX-1 in the 
impairment of hippocampal neurogenesis and 
proliferation following LPs-induced inflamma-
tion. The authors showed that LPs reduces 
progenitor proliferation and neurogenesis in 
wild-type but not in COX-1-/- mice, pointing 
to an essential role for COX-1 in propagating 
the inflammatory response and modulating 
the neurogenic niche.9 Hence, COX-1 emerges 
as a potential therapeutic target in inflamma-
tory neurodegenerative diseases. intriguingly, 
the epidemiological data indicating that non- 
steroidal anti-inflammatory drugs (nsAiDs) 
can affect the pathophysiology of major 
inflammation-driven neurodegenerative dis-
eases, such as Alzheimer disease and multiple 
sclerosis, indirectly suggest that some of their 
protective effects may be related to COX-1 inhi-
bition.8 Further investigations will be required 
to elucidate the downstream effectors of this 
modulation of neurogenesis and how neuro-
inflammation relates to the pathophysiology 
of neurodegenerative diseases.
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Mre11 is a component of the multifaceted 
Mre11-Rad50-nbs1 (MRn) complex, which 
influences key responses to DsBs, including 
ATM activation and DsB repair.8 The authors 
demonstrated that Mre11 is essential for the 
phosphorylation of AKT at ser-473 upon DnA 
damage. This is presumably due to the role 
of the MRn complex in ATM activation, as 
AKT phosphorylation is similarly abrogated in 
ATM-null fibroblasts and in normal fibroblasts 
treated with an ATM inhibitor. importantly, 
AKT phosphorylation requires histone ubiq-
uitination, and AKT activation is abrogated in 
cells deficient in the ubiquitin ligase RnF168, 
whose recruitment to DsBs is dependent upon 
ATM. Histone ubiquitination is important for 
the assembly of DDR proteins at DnA damage 
sites9 and could also serve to stabilize AKT 
and/or a putative AKT kinase at DsBs. These 
results reveal a Mre11-ATM-RnF168 axis that 
might work at multiple levels to recruit AKT to 
DsBs and to promote its activation. 
On another significant note, while a num-
ber of studies have shown that AKT is activated 
by DsBs, the localization of AKT at damage 
sites was not convincingly demonstrated 
previously. However, Fraser et al. unequivo-
cally showed the colocalization of AKT with 
γH2AX (a surrogate marker for DsBs) and 
with phospho-ATM (the active form of this 
kinase) by using three complementary meth-
ods to generate DsBs.7 intriguingly, they found 
that only pAKT-s473 accumulates at breaks, 
while pAKT-T308 is pan-nuclear. Future studies 
should shed more light on the dynamics of 
AKT activation at DsBs.
interestingly, this report also demonstrates 
that AKT contributes to the repair of DsBs by 
non-homologous end joining (nHeJ).7 This is 
consistent with a number of reports indicat-
ing that AKT might act upstream of the nHeJ 
protein DnA-PKcs.2 Moreover, a recent study 
demonstrated that AKT also promotes DsB 
repair by upregulating Mre11 expression in 
response to iR.10 These data raise the possibil-
ity of positive feedback loops between AKT 
and DnA repair proteins at damage sites, the 
net outcome of which would be efficient DsB 
repair as well as enhanced cell survival. 
it is important to point out that results from 
different groups implicating either DnA-PKcs 
or ATM in AKT activation are not that discrep-
ant, as it is becoming increasingly clear that 
ATM and DnA-PKcs have some overlapping 
roles in vivo.11,12 it will be important to eluci-
date whether the effect of ATM on ser-473 
phosphorylation occurs via activation of a 
putative kinase (that is, perhaps, distinct from 
mTORC2) or inactivation of a phosphatase 
acting at this site or due to conformational 
changes in AKT triggered by protein-protein 
interactions at a DsB. This report and preced-
ing studies suggest a great degree of complex-
ity in the regulation of AKT and validate the 
existence of cross-talk between RTK-Pi3K-AKT 
and DDR pathways. it is critical to understand 
the mechanisms underlying this cross-talk for 
the design of rational therapeutic strategies 
that could disrupt these connections for the 
radiosensitization of tumors with hyperacti-
vated Pi3K-AKT signaling.2,4
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Cells respond to myriad cues from neigh-
boring cells or from their extracellular envi-
ronment by various mechanisms, the best 
understood of which involves signaling at the 
cell membrane by receptor tyrosine kinases 
(RTKs). interestingly, recent reports indicate 
that certain RTKs, such as eGFR, as well as 
their downstream components, Pi3K and AKT, 
translocate into the nucleus in response to 
DnA double-strand breaks (DsBs), accumulate 
at the sites of DnA damage and directly influ-
ence DnA repair and other processes.1,2 in 
response to DsBs, three central kinases, ATM, 
ATR and DnA-PKcs, trigger a DnA damage 
response (DDR) that culminates in chroma-
tin remodeling, DnA repair, cell cycle arrest, 
programmed cell death and gene expression 
changes.3 importantly, all three kinases have 
been implicated in the activation of AKT in 
response to DnA damage.
AKT is a serine/threonine kinase and con-
stitutes a common downstream node at which 
signals from multiple RTKs converge. The 
activation of AKT upon mitogenic stimula-
tion requires its phosphorylation at Thr-308 
by PDK1 and at ser-473 by mTORC2. Once 
activated, AKT influences multiple biological 
responses, including cell survival, proliferation, 
translation and metabolism.4 The activation of 
AKT upon DnA damage involves its phosphor-
ylation at ser-473 in a DnA-PKcs-dependent 
manner; this occurs in the nucleus and results 
in the triggering of pro-survival pathways.5 
Other reports have also implicated ATM in the 
activation of AKT in response to both iR and 
insulin, but the underlying mechanism(s) are 
not well worked out.6
A report in the July 1st issue of Cell 
Cycle by Bristow and colleagues solidifies 
the connection between ATM and AKT by 
demonstrating that “Mre11 promotes AKT 
phosphorylation in direct response to DsBs.”7 
DNA double-strand breaks make bedfellows of ATM and AKT
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Autophagic tumor stroma: A biofuel for cancer growth
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To fulfill the energetic demands for growth, 
cancer cells support their metabolism with 
several nutrients available in circulation and 
interstitial fluid, including glucose, glutamine 
and lactate.1 notably, oncogenic mutations 
coupled to hypoxic conditions allow the 
tumor cells to metabolize glucose to pyru-
vate then pyruvate to lactate. This allows the 
regeneration of the nAD+ pool required for 
the glycolytic flux to meet the demand for 
ATP production and biosynthetic precursors, 
a phenomenon called the “warburg effect” 
when it occurs in the presence of oxygen.2
Recently, Lisanti and colleagues have 
put forward an iconoclastic hypothesis that 
focuses on the tumor stroma as the central 
fuel generator for cancer growth, the so-called 
“reverse warburg effect.”3-5 During starva-
tion, cells undergo autophagy (self-eating). 
This process is mediated by the formation of 
large autophagosomes within which hydro-
lases, acting at low pH, digest organelles, such 
as mitochondria and endoplasmic reticulum, 
thus providing amino acids, lipids and sug-
ars for survival. The prevailing theory is that 
tumor cells modify their metabolism in order 
to fuel their own growth. The new hypoth-
esis of Lisanti and colleagues argues that the 
warburg effect is occurring in tumor stromal 
cells, such as fibroblasts, which lose their mito-
chondria by autophagy and mitophagy, thus 
generating the energy necessary to fuel cancer 
growth.
How is the reverse warburg effect accom-
plished at the cellular and molecular level? 
First, cancer cells induce oxidative stress in qui-
escent fibroblasts by releasing reactive oxygen 
species (ROs) and inducing caveolin-1 (Cav-1) 
degradation (Fig. 1).6 Cav-1-deficient fibro-
blasts dramatically promote tumor growth in 
breast carcinoma xenografts,7 and the absence 
of stromal Cav-1 expression predicts poor clini-
cal outcome in breast cancer patients.8 in the 
June 15th issue of Cell Cycle, Castello-Cros and 
colleagues report that loss of Cav-1 in mam-
mary stromal fibroblasts leads to upregula-
tion of plasminogen activator inhibitor type 1 
and 2 (PAi-1/2).9 Fibroblasts overexpressing 
PAi-1/2, similar to Cav-1-deficient fibroblasts, 
promote tumor growth and metastasis when 
co-injected with breast cancer cells and 
induce oxidative mitochondrial metabolism in 
adjacent cancer cells. Thus, loss of Cav-1 and 
overexpression of PAi-1/2 lead to activation 
of fibroblasts with increased expression of 
vimentin, calponin and fibronectin, all mark-
ers of activated fibroblasts.9 subsequently, the 
activated fibroblasts undergo autophagy and 
mitophagy with increased expression of the 
autophagic markers Beclin-1 and LAMP-1/2 
(Fig. 1). The autophagic fibroblasts then release 
ROs and lactate. ROs induces genomic insta-
bility in adjacent cancer cells, thereby favoring 
mutations that support survival and prolifera-
tion. Lactate, on the other hand, provides the 
major biofuel for cancer growth. The soluble 
lactate generated by autophagic fibroblasts 
together with tumor-derived lactate have two 
additional important bioactivities. First, lactate 
can be taken up by endothelial cells via the 
monocarboxylate transporter MCT1, thereby 
stimulating an autocrine nFkB/iL-8 path-
way10 to drive angiogenesis (Fig. 1). Lactate 
released by the tumor cells  —  both breast and 
colon cancer cells  —  via MCT4 is sufficient to 
stimulate iL-8-dependent angiogenesis and 
tumor growth.10 second, it is known that lac-
tate can also induce HiF-1a and, thus, veGFA 
expression. Both iL-8 and veGFA would trig-
ger pro-survival and pro-angiogenic activities, 
leading to additional “biofuel” advantageous 
to cancer growth.
The discovery that PAi-1/2 induces autoph-
agy and indirectly stimulates cancer growth 
and angiogenesis adds another piece to the 
puzzle of this rapidly evolving story. However, 
much still needs to be done. First and fore-
most, we need to elucidate the precise sig-
naling mechanisms involved in the complex 
cancer-stroma interactome. Although over-
whelming evidence points to the necessity of 
direct cell-to-cell contact, soluble factors could 
prove to be important. in addition to cell-
permeable constituents, such as ketones and 
lactate, larger receptor signaling complexes 
embedded in cancer-released exosomes could 
mediate this dialogue. The emerging evidence 
that DnA, mRnA and microRnAs could be 
transferred from one cell to another by piggy- 
backing in exosomes provides another clue 
Figure 1. schematic representation of the autophagic tumor stroma. Cancer cells produce ROs 
and downregulate Cav-1. This process leads to activation of quiescent fibroblasts and overpro-
duction of PAi-1/2, vimentin, calponin and fibronectin, all markers of activated fibroblasts. This 
leads to an autophagic phenotype characterized by increased autophagy markers (Beclin-1 and 
LAMP1/2), and loss of Cav-1 with subsequent production of lactate and ROs. Both lactate and ROs 
feed back onto the cancer cells providing “biofuel” for cancer growth and inducing additional 
mutations that would enhance survival. notably, lactate can also induce Hif-1a and thus veGFA, as 
well as nFkB and thus iL-8, which both stimulate angiogenesis.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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Protein degradation via the ubiquitin protea-
some system (UPs) is an important aspect of 
cell division control. The ability of a cell to rap-
idly and temporally degrade proteins allows 
for the phases of the cell cycle to proceed 
in an orderly fashion and prevents potential 
interferences with downstream events. Protein 
degradation is essential for the initiation of 
DnA replication, chromosome segregation 
and exit from mitosis. However, studies over 
the past decade have shown that protein 
degradation is often perturbed in cancer cells, 
and this can lead to abnormal cell cycle pro-
gression, genetic instability and uncontrolled 
proliferation.
Proteins are targeted to the UPs by a 
class of enzymes termed ubiquitin ligases. An 
important family of these are the sCF-type 
ubiquitin ligases which are multiprotein com-
plexes generally composed of a cullin (usually 
Cul1), the RinG-finger protein Rbx1, skp1 and 
an F-box protein. F-box proteins (named for 
their ~40 amino acid F-box motif, which allows 
for their association with the adaptor pro-
tein skp1) function as substrate recognition 
components of the ubiquitin ligase. There are 
~70 different F-box proteins in humans, each 
targeting a unique set of protein substrates for 
ubiquitylation. 
The first evidence that suggested sCF ubiq-
uitin ligases could play an important role in cell 
division control came from reports that showed 
a protein complex consisting of skp1, Cdc53 
(Cul1 homolog) and the F-box protein Cdc4 tar-
geted the cyclin-dependent kinase (Cdk) inhib-
itor sic1 for degradation in budding yeast.1-2 
Over the past decade, the homologous ubiq-
uitin ligase in humans (termed sCFhCdc4, sCFFbxw7 
or sCFFbw7) has been a subject of intense inves-
tigation.3,4 we now know that sCFFbw7 mediates 
the degradation of several key regulators of cell 
division, including cyclins  e1/2, c-Myc, c-Jun, 
c-Myb, notch and mTor.3,4 Recently, sCFFbw7 was 
also linked to apoptosis regulation through tar-
geted degradation of the Bcl-2 family member 
and pro-survival protein Mcl1.5,6
in the July 1st issue of Cell Cycle, Lerner 
et al. reported that sCFFbw7 activity is regulated 
by the micro-RnA miR-27a.7 in normal cell 
division cycles, Fbw7 expression was shown to 
be subject to miR-27a-dependent repression 
from G2 through early G1 phase, thus allowing 
sCFFbw7 substrates to accumulate and cyclin e 
to initiate an s-phase program. However, 
at G1/s boundary, the miR-27a-dependent 
repression of Fbw7 is lifted, which promotes 
the degradation of cyclin e and presumably 
other sCFFbw7 substrates. Therefore, miR-27a 
coordinates with transcriptional regulation 
(of CCne) and temporal phosphorylations to 
ensure that cyclin e expression is restricted to 
late G1 phase of the cell cycle. The importance 
of miR-27a in cell division control was demon-
strated by experiments that showed enforced 
expression of miR-27a induced severe cell 
cycle defects, including premature entry into 
s phase, delayed s-phase progression and 
signs of replication stress. interestingly, these 
phenotypes are also found in cells that express 
deregulated cyclin e, which is known to inter-
fere with pre-replication complex assembly.
since sCFFbw7 regulates the degradation 
of several key oncoproteins, it is subject to 
intense pressure for functional inactivation in 
cancer cells. Loss of sCFFbw7 function has been 
shown to promote cell cycle dysregulation, 
uncontrolled proliferation, genetic instability 
and chemotherapy resistance.3-4 Data from 
M. Lerner et al. suggests that overexpression 
of miR-27a may represent a novel mechanism 
of sCFFbw7 inactivation in cancer cells. miR-27a 
was found to be overexpressed in many 
pediatric B-ALLs, and its expression inversely 
correlated with Fbw7 levels in hyperdiploid 
pre-B-ALLs.7 This data suggests that miR-27a 
overexpression could be oncogenic in these 
cancers by repressing Fbw7 expression, thus 
promoting the dysregulation of sCFFbw7’s onco-
protein substrates (Fig. 1).
However, several questions of miR-27a’s 
regulation of sCFFbw7 remain unanswered. How 
does miR-27a-dependent repression of Fbw7 
become derepressed at the G1/s boundary to 
activate sCFFbw7 in normal cell cycles? is miR-
27a overexpression sufficient to functionally 
inactivate sCFFbw7 in cancer cells, and what is 
the importance of this mechanism relative 
to other known mechanisms of inactivation 
(Fig. 1)? Future studies aimed at understand-
ing the molecular regulation of miR-27a- 
dependent repression of Fbw7 and functional 
and tumorgenicity assays will likely provide 
answers to these questions and, ultimately, 
help to define the importance of miR-27a in 
the regulation of normal cell division cycles 
and its dysregulation in cancers.
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to this puzzle. Thus, cancer cells could transfer 
molecular “tool kits” that may, in turn, lead to 
a radical modification of the quiescent stroma 
into a self-destructing and energy-producing 
one that would promote angiogenesis and 
feed the tumor cells with extra biofuel.
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Taccalonolides: A microtubule stabilizer poses a new puzzle with old pieces
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The structural diversity of microtubule tar-
geting agents (MTAs) is breathtaking, from 
simple bicyclics, like combretastatins, to 
complex compounds, like epothilones and 
halicondrins. The taccalonolides, plant-
derived steroids described by Risinger and 
Mooberry in the July 1st issue of Cell Cycle,1 
fall somewhere in the middle of this structural   
complexity.
interest in MTAs as chemotherapeutics 
began with the use of vincristine to treat 
acute lymphoblastic leukemia in the 1950s 
and shows no sign of abating. All MTAs inhibit 
mitosis in rapidly growing cells, though clini-
cal efficacy against patient tumors is likely due 
to non-mitotic activities.2 The success of MTAs 
as chemotherapeutics has fueled searches for 
new compounds, one result being the tac-
calonolides. notably, unlike agents against 
other cellular targets, MTAs remain principally 
natural products or semi-synthetic deriva-
tives. That diverse organisms produce MTAs as 
toxins underscores the crucial roles of MTs in 
many cellular functions, continuing to make 
MTs attractive targets. The variability of MTAs 
likely explains their diverse antitumor profiles 
and varying neurotoxicty. This variability may 
yet lead to agents with different antitumor 
activity and hopefully less neurotoxicity, and 
this possibility continues to encourage pursuit 
of MTAs as cancer therapeutics.
in the July 1st issue, Risinger and Mooberry 
discussed several features of taccalonolides 
that distinguish them from paclitaxel and 
other MT-stabilizers: (1) a novel structure, 
(2)  MT activity in cells not reproduced with 
purified tubulin or cell extracts, (3) cellular 
activity much less reversible than with other 
MTAs and (4) concentrations effective in inter-
phase and mitotic cells that are very similar, 
unlike the differential seen with paclitaxel. we 
discuss these below.
 The MT activity of taccalonolides was dem-
onstrated by mitotic arrest and accumulation 
of MT bundles in interphase cells, evidence 
that taccalonolides, like taxanes, epothilones, 
laulimalide and peloruside, stabilize MTs. 
Taccalonolides as steroids are quite different 
structurally from other MT stabilizers, but tac-
calonolides are not the only MT-stabilizing ste-
roid. A synthetic derivative with paclitaxel-like 
activity was discovered years ago in a search 
of analogs of the natural estrogen metabolite 
2-methoxyestradiol, itself a weak MT destabi-
lizer. This steroid derivative demonstrated pro-
nounced MT stabilization with purified tubulin 
but not with cells,3 the opposite effect of that 
observed with taccalonolides.
Taccalonolides are unusual, since their cel-
lular activity is not reproduced in vitro. Unlike 
Figure 1. Mechanisms of sCFFbw7 functional inactivation in cancer. Allelic deletions, promoter methylations and mutations of the FBW7 gene have been 
detected in a variety of human cancers.3-4 M. Lerner et al. recently found that Fbw7 expression is also negatively regulated by the micro-RnA miR-27a, 
which is overexpressed in pediatric B-ALLs and hyperdiploid pre-B-ALLs.7 Functional inactivation of sCFFbw7 has been shown to promote cell cycle 
deregulation, uncontrolled proliferation, genetic instability and resistance to chemotherapy. Alterations found in cancer cells are indicated in red.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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in proliferating cells, genome integrity is 
maintained by checkpoint mechanisms that 
“recognize” lesions in DnA and/or chroma-
tin and “orchestrate” a coordinated response 
of the cell cycle and DnA repair machines 
to prevent the replication or segregation of 
damaged genome.1 Almost a decade ago, 
Puri et al.2 provided the first evidence for 
a “differentiation checkpoint,” showing that 
muscle-specific gene expression is inhibited 
when DnA damaged myoblasts are induced 
to undergo terminal differentiation. That study 
identified tyrosine phosphorylation of MyoD 
by the nuclear ABL tyrosine kinase as a key 
event in inhibiting the transactivation function 
of MyoD following DnA damage.2 However, it 
was unclear whether MyoD inhibition is part of 
the cell cycle checkpoint mechanism or a par-
allel pathway unique to myoblasts. simonatto 
et al.3 provided answers to these questions in 
the July 15th issue of Cell Cycle. 
By treating myoblasts with a panel of 
genotoxins that induce G1/s or G2/M arrest, 
simonatto et al. showed that MyoD is inhib-
ited at both checkpoints. This inhibition of 
muscle-specific gene expression is reversed 
with time and closely correlated with the 
repair of DnA lesions. Thus, a myoblast with 
damaged DnA does not differentiate until the 
genome is repaired (Fig. 1). it is shown that 
iGF1 and caffeine specifically and respectively 
abolish genotoxin-induced MyoD inhibition 
and the G1/s and the G2/M cell cycle check-
points in myoblasts (Fig. 1), demonstrating 
that the differentiation checkpoint is part 
Checking before changing: Cell cycle checkpoints inhibit muscle differentiation
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paclitaxel and other MT stabilizers, taccalo-
nolides do not induce MT assembly using 
purified tubulin or cell extracts. it is assumed 
that taccalonolides act by binding tubulin, 
but direct binding data demonstrating this 
are lacking, and, in fact, one study found an 
absence of binding and an inability to displace 
other MT stabilizers from tubulin.4
Other MTAs exhibit discordance between 
activity in cells and with purified proteins. 
Dolastatin 15 and the 2-methoxyestradiol 
derivative mentioned above are examples. 
Dolastatin 15 is a MT-destabilizing peptide 
that is very potent in cells (Gi50 1000-fold 
lower than taccalonolides), but it inhibits 
polymerization of purified tubulin very poorly 
and does not inhibit binding of other MTAs 
to tubulin. Dolastatin 15 was ultimately 
shown to bind tubulin,5 but the discordance 
between its in vivo and in vitro activities 
remains notable compared to other MTAs 
and is worth remembering in the context of 
taccalonolide activities described by Risinger 
and Mooberry.
The cellular effects of taccalonolides are 
less reversible on removal of drug than is 
observed with paclitaxel. This persistence 
suggests that the drug may be significantly 
retained once inside the cell compared to 
most MTAs. Again, MTA diversity provides 
another example. Dolastatin 10 binds tightly 
to tubulin and is highly retained in cells;6 
these properties likely contribute to its very 
low Gi50. in contrast, taccalonolides show 
Gi50 values ~105-fold higher than dolastatin 
10 and appear not to bind tightly to tubu-
lin. it will be interesting to reevaluate this 
with a labeled taccalonolide. while durabil-
ity of drug effect may be seen as desirable, 
it may be a mixed blessing for a chemo-
therapeutic, since irreversibility could increase   
neurotoxicity.
Finally, the suggestion that taccalonolides 
may target interphase MTs more efficiently 
than other MTAs is intriguing. if this is a new 
wrinkle on MTA activity, it may manifest as 
greater activity against slow-growing cells and 
human tumors compared to other MTAs. These 
various activities make the taccalonolides 
compounds to watch as the puzzles described 
in this paper are solved.
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Figure 1. DnA damage-induced muscle differentiation checkpoints. Genotoxins activate two 
differentiation checkpoints at G1/s and G2/M to inhibit MyoD-dependent muscle gene expression 
in DnA damaged myoblasts.  These checkpoints are reversible, as differentiation can resume after 
DnA is repaired.  inhibition of MyoD (depicted as the small green cylinder) is mediated by the cell 
cycle checkpoints, because inhibitors of the G1/s or G2/M cell cycle arrest, i.e., iGF1 or caffeine, also 
block the differentiation/arrest, respectively. in G1/s-arrested myoblasts, MyoD remains associated 
with the promoters of muscle-specific genes but does not stimulate transcription. in G2/M- 
arrested myoblasts, MyoD dissociates from DnA and is thus unable to stimulate muscle-specific 
gene expression.©2 0 1 1   L a n d e s   B i o s c i e n c e .
D o   n o t   d i s t r i b u t e .
www.landesbioscience.com  Cell Cycle  3235
of the cell cycle checkpoint mechanisms. it 
is also shown that MyoD association with 
muscle-specific promoters is maintained in 
G1/s-arrested cells; however, MyoD is unable 
to elaborate the appropriate histone modi-
fications required for transcription (Fig. 1). 
However, MyoD is not able to associate with 
DnA in G2/M arrested cells (Fig. 1). These 
results demonstrate that the G1/s and the 
G2/M cell cycle checkpoints employ different 
means to prevent MyoD from driving muscle 
differentiation.
The differentiation-arrest activated in myo-
blasts appears to contradict the biological 
principle that cell cycle arrest and terminal 
differentiation are tightly linked. For example, 
the RB family of pocket proteins, p130, p107 
and pRB, inhibit G1/s transition but stimulate 
muscle differentiation.4 A role for nuclear ABL 
in inhibiting MyoD,2 also demonstrated in 
mice,5 is initiating the differentiation check-
point, but because activated RB inhibits ABL,6 
this only results in a transient modification 
of MyoD.2 Thus, cell cycle checkpoints must 
inhibit MyoD through multiple mechanisms. 
Of note is the physiological factor Myostatin, 
which inhibits both the proliferation and the 
differentiation of myoblasts.7 Myostatin inhib-
its the activity of the Cyclin e-Cdk2 complex, 
leading to the dephosphorylation of nPAT, 
a nuclear protein required for histone gene 
expression.8 nPAT also plays a key role in DnA 
damage-induced G1/s arrest.9 Thus, Cyclin-e-
Cdk2 inhibition and possibly nPAT dephos-
phorylation may also contribute to the G1/s 
differentiation checkpoint. Much remains to 
be learned about the differentiation check-
points, and the work of simonatto et al. has 
pointed the way forward.
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The wild-type p53-induced phosphatase 1 
(wip1, also-called PPM1D) is a type 2C protein 
phosphatase (PP2Cδ) that requires Mg2+ or 
Mn2+ for catalytic efficacy and is insensitive to 
phosphatase inhibitor okadaic acid. wip1 was 
originally identified as a p53-induced gene in 
response to ionizing radiation.1 subsequent 
studies indicated that wip1 acts as a homeo-
static regulator of the DnA damage response, 
facilitating the return of cells to a normal pre-
stress state following repair of damaged DnA.2-3 
in addition, wip1 inhibits several tumor sup-
pressor pathways, including ATM-CHK2-p53 
and p38MAPK-p53.2 Furthermore, wip1 is 
found to be aberrantly expressed in several 
types of human cancers, and wip1-null mice 
are resistant to cancer.4-5 These unique features 
make wip1 an oncogenic phosphatase and 
a promising drug target for cancer therapy.
The p53 tumor suppressor plays a pivotal 
role in preserving the integrity of the genome 
and in preventing cancer development. The 
importance of p53 in this process is demon-
strated by the fact that inactivation of p53 
occurs in over 50% of human cancers, and 
loss of p53 function is known to be essential 
for carcinogenesis.6 in response to various 
cellular stresses, p53 is activated and func-
tions as a sequence-specific DnA binding tran-
scriptional factor to induce its downstream 
targets, which mediate cell cycle arrest, DnA 
repair, and apoptosis.7 Consistently, numerous 
studies have shown that p53 exerts pivotal 
roles in guarding genomic stability under 
stress conditions.6
Most studies on wip1 have been focused 
on how wip1 facilitates the return of cells to 
homeostasis after DnA damage. The study 
by Park et al. convincingly showed that under   
non-stress conditions, wip1 plays a critical role 
in p53-mediated cell homeostasis. specifically, 
they showed that wip1 is able to induce 
G2/M arrest in cells with wild-type p53 but 
not the ones with mutant p53. in addition, 
wip1-mediated G2/M arrest is able to decrease 
cell death in mouse embryonic fibroblasts. 
To uncover the underlying mechanism, they 
showed that wip1 is able to decrease Cdc2 
kinase activity by increasing phosphorylation 
of the inhibitory tyrosine-15 of Cdc2. Together, 
the current studies suggest that, under non-
stress conditions, wip1 collaborates with p53 
to induce G2/M arrest, which enables normal 
cells to be ready for mitosis and avoid mitotic 
catastrophe. similarly, this regulation favors 
cancer cells with wild-type p53 to escape 
from the mitotic checkpoint and, thus, pro-
motes tumor formation. Therefore, targeting 
wip1 in cancer cells with wild-type p53 may 
lead to a shorter G2 preparation and render 
cell death via mitotic catastrophe. in sup-
port of this notion, wip1 inhibition has been 
shown to decrease cancer cell proliferation in 
a p53-dependent manner.8-9
At this point, it still remains unclear how 
wip1 induces G2/M arrest in cells with wild-
type p53. it will be interesting to address how 
wip1 increases the phosphorylation of the 
inhibitory tyrosine-15 of Cdc2. Additionally, 
is there any other mechanism by which wip1 
inhibits Cdc2 kinase activity? Finally, it will also 
be interesting to address how p53 modulates 
wip1-induced G2/M arrest under non-stress 
conditions, which will advance our under-
standing of how p53 makes cell fate decisions. 
Although much work remains to be explored, 
these findings clearly highlight a novel role 
of wip1 in p53 guarding homeostasis under 
non-stress conditions. The work also shed a 
light on a novel mechanism by which wip1, in 
addition to its ability to inhibit p53, promotes 
tumorigenesis by helping cancer cells escape 
from the mitotic checkpoint. 
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Lamins are components of the nuclear lamina, 
a protein network that provides a framework 
for the nuclear envelope and interacts with 
chromatin and the cytoskeleton. Lamins A 
and C are encoded by the same gene (LMNA) 
by alternative splicing. Lamin A undergoes 
serial post-translational modifications on the 
CaaX-box at its C terminus: (1) farnesylation 
of the cysteine, (2) cleavage of the -aaX tri-
peptide, (3) methylation of the farnesylated 
cysteine and (4) proteolytic removal of the 
15-residue C-terminal peptide containing the 
farnesylated cysteine. Mutations in LMnA 
that preclude this proteolytic processing or, 
in  FACE1/Zmpste24, the gene encoding its 
processing enzyme,1 cause human premature 
aging diseases, such as Hutchinson-Gilford 
progeria syndrome (HGPs) and restrictive 
dermopathy (RD).2 Other mutations in LMnA 
are responsible for a variety of human dis-
eases, collectively known as laminopathies. 
However, the molecular mechanisms underly-
ing the phenotypic heterogeneity of these 
genetic disorders remain obscure, although 
a genome-wide alteration of the epigenome 
might explain it partially.3
in a previous study, susana Gonzalo’s group 
shed some new light onto the functional role 
of lamin A.4 it was already known that lamins 
participate in the maintenance of genomic 
stability through the stabilization of 53BP1, 
a component of the DnA damage response 
pathway (DDR).5,6 Thus, embryonic fibroblasts 
lacking lamin A/C exhibited increased basal 
levels of γH2AX, chromosome breaks, defects 
in telomere chromatin architecture, impaired 
maintenance of telomere length and, most 
importantly, a hindered ability to process dys-
functional telomeres by long-range nHeJ.5 
in their more recent work, the same group 
went beyond and provided experimental evi-
dence showing that lamins also participate in 
the short-range DsB repair pathway induced 
by ionizing radiation, apparently in a 53BP1-
dependent manner.
The competition between the nHeJ and 
the high-fidelity homologous recombina-
tion repair pathways (HR) is well-established. 
However, and contrary to this general rule, 
lamin A/C-deficient cells with decreased nHeJ 
repair were not more proficient in the HR path-
way. intriguingly, Redwood et al. showed that 
the HR pathway is compromised in lamin A/C-
deficient cells by transcriptional downregula-
tion of RAD51 and BRCA1, two key components 
of the HR machinery. Accordingly, lamins- 
deficient cells exhibit increased radiosensi-
tivity.4 By following an intelligent candidate 
approach, they were able to experimentally 
demonstrate that this transcriptional inhibition 
was carried out specifically by the repressor 
complex formed by the Rb family member 
p130 and e2F4. This is the first time that lamins 
were shown to be involved in the transcrip-
tional regulation of the HR repair pathway. This 
observation is of special interest considering 
that HGPs and Zmpste24-/- fibroblasts have 
increased nHeJ activity at expense of a reduc-
tion of HR (Fig. 1).6 Thus, subtle variations in 
lamin A function might affect the DDR pathway 
in very different manners, such as destabiliz-
ing 53BP1 and RB or downregulating RAD51/
BRCA1. Unraveling the specific alterations 
associated to each LMNA mutation will facili-
tate understanding the role of DDR defects in 
the development of human laminopathies.
Much has been learned about the func-
tion of lamins in DnA repair over the last 
years. Lamin A/C-deficient mice do not show 
an increased rate of tumorigenesis7 despite 
the severe defects in the two main pathways 
of DnA repair (nHeJ and HR) reported by 
Gonzalo’s group. This fact, together with the 
observed repair of DnA DsBs in the absence of 
canonical nHeJ and HR in laminA/C-deficient 
MeFs, points towards the in vivo operation of 
alternative DDR repair pathways and opens up 
new avenues for research in the field.
Finally, it is interesting to note that LMNA 
expression is reduced/absent in undifferenti-
ated or proliferative cells but is observed in 
differentiated or non-proliferative cells, such 
as quiescent adult stem cells. Taken together, 
and considering the link between age-related 
nuclear envelope defects, DnA damage 
accumulation and stem cell dysfunction in 
HGPs,8,9 it becomes now more evident that 
the therapeutic response of a tumor (i.e., radio- 
resistance) can be drastically affected by the 
status of LMnA expression in the cancer stem 
cells and their niches.
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Figure 1. Lamin A and genome stability. in the absence of lamin A/C, the structure of the nuclear 
envelope is compromised and the stability of 53BP1 is decreased, causing a reduction in the nHeJ 
repair pathway. However, lamin A/C deficiency also leads to increased formation of p130/e2F4 
complexes, which in turn bind to the RAD51 and BRCA1 promoters, inhibiting their transcription 
and ultimately provoking a reduction in the HR repair pathway.